Donanemab Slowed Cognitive Decline in Lilly’s Phase 3 Alzheimer’s Study

Last week Eli Lilly and Company announced that nearly half of the participants on their early Alzheimer’s drug donanemab had no clinical progression at 1 year. The study showed donanemab treatment slowed clinical decline by 35% compared to placebo and resulted in 40% less decline in the ability to perform activities of daily living. Based […]

Donanemab Slowed Cognitive Decline in Lilly’s Phase 3 Alzheimer’s Study Read More »